Loading stock data…
Cellebrite DI Ltd (CLBT)
$14.18+0.42 (+3.05%)
Market ClosedLast close Jun 29
Cellebrite DI Ltd.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cellebrite DI Ltd. in the Technology sector is trading at $14.18 with a market capitalization of $3.2B. Wall Street consensus targets $21.00 (7 analysts), implying a +48.1% move over the next 12 months. The stock is currently 29% below its 52-week high of $19.98, remaining 9.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +48.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $128.30M↓ | $128.82M↑ | $126.03M↑ | $113.28M↑ | $107.55M |
| Gross Profit | $105.88M↓ | $109.13M↑ | $105.72M↑ | $95.60M↑ | $90.06M |
| Operating Income | $9.12M↓ | $20.80M↑ | $18.99M↑ | $14.42M↑ | $12.27M |
| Net Income | $10.94M↓ | $21.26M↑ | $20.19M↑ | $19.48M↑ | $17.40M |
Peer Comparison
AAPLMSFTGOOGL
Fundamentals
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, ext...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.08%
Volume
Today's trading volume
1.84M
Recent News
Cellebrite (CLBT)’s Total Addressable Market Is Large, Growing, And Likely Understated, According To DA Davidson
With an upside potential of 56.13%, Cellebrite DI Ltd. (NASDAQ:CLBT) ranks among the stocks under $20 that will explode. Cellebrite (NASDAQ:CLBT) received a fresh vote of confidence from Wall Street, and the timing aligns with a quarter that gave analysts plenty to analyze. On May 27, 2026, DA Davidson initiated coverage of Cellebrite DI Ltd. […]
Is Cellebrite DI Ltd. (CLBT) A Good Stock To Buy Now?
Is CLBT a good stock to buy? We came across a bullish thesis on Cellebrite DI Ltd. on InfoArb Sheets’s Substack. In this article, we will summarize the bulls’ thesis on CLBT. Cellebrite DI Ltd.’s share was trading at $12.47 as of June 17th. CLBT’s trailing and forward P/E were 45.75 and 35.71 respectively according to Yahoo […]
Cognyte's Recurring Revenue Shift: Short-Term Strain Ahead?
CGNT's shift to recurring revenues boosts visibility, but subscription transition pressures cash flow and near-term financial performance.
Tracking How the Cellebrite (CLBT) Investment Narrative Is Evolving Without New Analyst Targets
The latest update on Cellebrite DI keeps the existing price targets unchanged, with no revisions signaled in this round of analysis. With target levels holding steady, you can focus on how the stock’s story may shift as new research and data points emerge. Read on to see how to track these updates and stay on top of the evolving analyst narrative around Cellebrite DI. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value...
Cognyte to Report Q1 Earnings: How Should Investors Play the Stock?
CGNT to report fiscal Q1 2027 on June 3 as revenues expected to be up 10.2% to $105.3M.